Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Appointment of Non-Executive Director – Mary Sontrop

Mar 5, 2021Mark EdwardsNews

5 March 2021

ASX ANNOUNCEMENT

Appointment of Non-Executive Director – Mary Sontrop

Medical Developments International Limited (ASX: MVP) is pleased to announce the appointment of Ms. Mary Sontrop as a Non-Executive Director of the Company with immediate effect.

Mary has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration.  During her 28 years with CSL Limited (ASX: CSL), Mary was an integral part of CSL’s globalisation through a series of major acquisitions.  This included primary responsibility for the turnaround of unprofitable manufacturing operations.  Subsequently as head of global plasma manufacturing, Mary delivered a globally integrated manufacturing network spanning four countries.  As head of CSL’s Australia and New Zealand pharmaceutical business, Mary and her team delivered Australia’s most successful adolescent/adult immunisation program and achieved USFDA (US Food & Drug Administration) approval to manufacture and export CSL’s seasonal and pandemic influenza vaccines.

Mary holds a Bachelor of Applied Science, Graduate Diplomas in Quality Management and Administration (Health) and a Master of Business Administration.  Mary is an experienced non-executive director (currently on the Board of IDT Australia Ltd (ASX: IDT)) and a Graduate of the Australian Institute of Company Directors.  She also has significant international governance experience.

Mary said: “Whilst I recognise that MVP is going through a challenging period of change, I am very much looking forward to working with the Company Board and management to realise the international potential of this Australian technology”.

MVP Company Chair, Mr. Gordon Naylor said: “Mary joins at a critical time for the company.  I am confident that she will strengthen the Board and readily bring valuable experience and counsel to the Company”.

Enquiries:

Mark Edwards

Company Secretary

+61 (3) 9547 1888

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter